Plus: Gilead’s Trodelvy fails to extend lives of lung cancer patients

| January 23, 2024 Check out STAT+ |
| --- |

|  |
| --- |

| Sponsored By   |
| --- |

| Craig F. Walker/Globe Staff STAT+ \| Dana-Farber cancer researchers moving to retract one paper, correct others in broad investigation of manipulated data Allegations of mishandled data involve four papers by Dana-Farber CEO Laurie Glimcher and scores by other top scientists. By Jonathan Wosen and Angus Chen Dana-Farber expands studies to be retracted to 6, plus 31 to be corrected over mishandled data The cancer center says it has taken prompt action in many of the cases that were recently flagged by a scientific-integrity blogger. By Angus Chen and Jonathan Wosen Mammograms are less effective for women with dense breast tissue. Medical experts disagree on what to do about it Screening for breast cancer is complicated by high fibroglandular density in breasts, and experts differ on multiple options for supplementing mammograms. By Annalisa Merelli Yichuan Cao/Sipa USA via AP Images STAT+ \| Gilead’s Trodelvy fails in lung cancer and raises new questions on antibody drug conjugate drugs The result, from a closely watched study called Evoke-01, will be seen as a disappointment by investors and oncologists alike. By Matthew Herper |
| --- |

| More around STAT |
| --- |

|  |
| --- |

|  |
| --- |

|  |
| --- |

| Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles. |
| --- |

---

| Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play |
| --- |

|  |
| --- |

|              STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails |
| --- |

| Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser |
| --- |